Compare
BioXcel Therapeutics, Inc. vs Polomar Health Services, Inc. vs Vaccinex, Inc. vs Yarrow Bioscience, Inc.
| Latest fiscal year | BioXcel Therapeutics, Inc. BTAIQ | Polomar Health Services, Inc. PMHS | Vaccinex, Inc. VCNXLast annual report: year ended 2024-12-31 | Yarrow Bioscience, Inc. YARW |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 |
| Revenue | $642.0K | $648.2K | $601.0K | $570.0K |
| Revenue growth (YoY) | -71.7% | n/m | +5.4% | +13.8% |
| Gross margin | 74.5% (computed) | 71.0% | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$69.90M | -$10.70M | -$18.63M | -$26.48M |
| EPS (Diluted) | -$5.73 | -$0.39 | -$8.88 | -$0.62 |
| Operating cash flow | -$57.62M | -$396.0K | -$16.19M | -$33.12M |
| Free cash flow | -$57.62M | n/a | -$16.21M | -$33.12M |
| Cash & equivalents | $28.41M | $132.2K | $1.11M | $24.03M |
| Total assets | $44.92M | $390.0K | $2.60M | $30.16M |
| Total liabilities | $140.38M | $1.61M | $5.08M | $2.40M |
| Shareholders' equity | -$95.46M | -$1.22M | -$2.49M | $27.77M |
| Return on year-end equity | n/a | n/a | n/a | -95.4% |
| Shares outstanding | 22.33M | 28.02M | 2.68M | 33.32M |
Revenue, most recent five fiscal years
| Fiscal year | BioXcel Therapeutics, Inc. | Polomar Health Services, Inc. | Vaccinex, Inc. | Yarrow Bioscience, Inc. |
|---|---|---|---|---|
| Latest | $642.0K Ended 2025-12-31 | $648.2K Ended 2025-12-31 | $601.0K Ended 2024-12-31 | $570.0K Ended 2025-12-31 |
| 1 year earlier | $2.27M Ended 2024-12-31 | $58.8K Ended 2024-12-31 | $570.0K Ended 2023-12-31 | $501.0K Ended 2024-12-31 |
| 2 years earlier | $1.38M Ended 2023-12-31 | $41.8K Ended 2023-12-31 | $275.0K Ended 2022-12-31 | $424.0K Ended 2023-12-31 |
| 3 years earlier | $375.0K Ended 2022-12-31 | $34.5K Ended 2022-12-31 | $900.0K Ended 2021-12-31 | $477.0K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $625.0K Ended 2020-12-31 | $931.0K Ended 2021-12-31 |